New Review of ctDNA Liquid Biopsies in Nature Reviews Cancer Co-Authored by Inivata CSO Nitzan Rosenfeld
Inivata, a global clinical cancer genomics company employing a revolutionary approach to circulating tumor DNA (ctDNA) analysis to improve personalized healthcare in oncology, today announces the publication of a new review of the use of ctDNA as a liquid biopsy for cancer treatment in the journal Nature Reviews Cancer co-authored by Inivata’s Chief Scientific Officer and Founder Nitzan Rosenfeld and Co-Founder and Clinical Advisor James Brenton.
In “Liquid biopsies come of age: towards the implementation of circulating tumour DNA” (available online at www.nature.com/nrc/journal/vaop/ncurrent/full/nrc.2017.7.html) the authors* review the potential of ctDNA in cancer diagnosis, treatment selection and monitoring disease burden. They also highlight the importance of assay sensitivity, as sampling often yields low concentrations of ctDNA, and review currently available approaches for sensitive detection.
The authors conclude that liquid biopsies have demonstrated broad potential clinical utility across a range of applications and they are beginning to be used for patient benefit.
*Jonathan C.M. Wan1,2, Charles Massie1,2, Javier Garcia-Corbacho3, Florent Mouliere1,2, James D. Brenton1,2, Carlos Caldas1,2,4, Simon Pacey2,4, Richard Baird2,4 and Nitzan Rosenfeld1,2.
1Cancer Research UK Cambridge Institute, 2Cancer Research UK Cambridge Centre, 3Clinical Trials Unit, Clinic Institute of Haematalogical and Oncological Diseases, Hospital Clinic de Barcelona, 4Department of Oncology, University of Cambridge Hutchison-MRC Research Centre.
About Nitzan Rosenfeld
Nitzan Rosenfeld is a senior group leader at the Cancer Research UK Cambridge Institute, University of Cambridge, and Inivata’s co-founder and CSO. Nitzan trained in Physics, and specialized in quantitative molecular biology, obtaining a Ph.D. in the field of Systems Biology from the Weizmann Institute of Science. In 2005 he joined Rosetta Genomics Ltd, where he was head of Computational Biology and led development of molecular diagnostic tests. In 2009 Nitzan joined Cancer Research UK’s Cambridge Institute. His research group combines molecular technologies with genomic approaches to develop new diagnostic strategies. The focus of current research, the application of circulating tumour DNA for personalised cancer diagnostics, formed the basis of Inivata. In 2013 Nitzan was awarded the CRUK Future Leaders in Cancer Research prize, the British Association for Cancer Research Translational Research Award, and a prestigious ERC Starting Grant. At the end of 2015, Nitzan received the Foulkes Medal which is awarded biennially to an outstanding bioscience researcher within ten years of completing their PhD.
Inivata is a leader in liquid biopsy. Its InVision® platform unlocks essential genomic information from a simple blood draw to guide and personalize cancer treatment, monitor response and detect relapse. Inivata’s technology is based on pioneering research from the Cancer Research UK Cambridge Institute, University of Cambridge. Its lead product, InVisionFirst®-Lung is commercially available and offers best-in-class sensitivity and turnaround, providing molecular insights that enable clinicians to make more informed treatment decisions for advanced NSCLC patients. Inivata has also launched the personalized RaDaR™ assay – allowing the highly sensitive detection of residual disease and recurrence. Inivata is partnering with pharmaceutical, biotechnology companies and commercial partners in a range of early and late stage cancer development programs. The Company has a CLIA certified, CAP accredited laboratory in Research Triangle Park, NC and R&D laboratories in Cambridge, UK. For more information, please go to www.inivata.com. Follow us on Twitter @Inivata.